Literature DB >> 28727474

A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities.

Samer Alkaade1, Ashley A Vareedayah.   

Abstract

Exocrine pancreatic insufficiency (EPI) is characterized by a deficiency of exocrine pancreatic enzymes, resulting in deficits in digestion of all macronutrients, with deficiencies in digestion of fats being the most clinically relevant. The leading cause of EPI is chronic pancreatitis. However, many other causes and conditions may be implicated, including cystic fibrosis, pancreatic duct obstruction, gastric and pancreatic surgery, diabetes mellitus and other conditions. Physical and biochemical causes of EPI include decreased production and secretion of lipase, increased lipase destruction, pancreatic duct obstruction, decreased lipase stimulation and degradation, as well as gastrointestinal motility disorders. EPI is largely diagnosed clinically, and is often identified by symptoms such as steatorrhea, weight loss, abdominal discomfort, and abdominal bloating. Lifestyle modifications (eg, smoking cessation, limiting or avoiding alcoholic drinks, and reducing dietary fat intake) and exogenous pancreatic enzyme supplements are commonly used to help restore normal digestion and absorption of dietary nutrients in patients with EPI.

Entities:  

Keywords:  Exocrine pancreatic insufficiency; EPI; RELiZORB; pancreatic enzyme replacement therapy; PERT; steatorrhea; cystic fibrosis; fat malabsorption; fatty acid deficiency; lipase; pancreatitis; chronic pancreatitis

Mesh:

Substances:

Year:  2017        PMID: 28727474

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  5 in total

1.  Trypsin may be associated with duodenal eosinophils through the expression of PAR2 in early chronic pancreatitis and functional dyspepsia with pancreatic enzyme abnormalities.

Authors:  Shuhei Agawa; Seiji Futagami; Hiroshi Yamawaki; Rina Tsushima; Kazutoshi Higuchi; Mayu Habiro; Rie Kawawa; Yasuhiro Kodaka; Nobue Ueki; Yoshiyuki Watanabe; Katya Gudis; Rhuji Ohashi; Katsuhiko Iwakiri
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

2.  Applying Machine Learning Techniques to Identify Undiagnosed Patients with Exocrine Pancreatic Insufficiency.

Authors:  Bruce Pyenson; Maggie Alston; Jeffrey Gomberg; Feng Han; Nikhil Khandelwal; Motoharu Dei; Monica Son; Jaime Vora
Journal:  J Health Econ Outcomes Res       Date:  2019-02-14

3.  Optimizing Clinical and Cost Outcomes for Patients on Enteral Nutrition Support for Treatment of Exocrine Pancreatic Insufficiency: Proceedings from an Expert Advisory Board Meeting.

Authors:  Joseph I Boullata; Janice L Clarke; Archie Stone; Alexis Skoufalos; David B Nash
Journal:  Popul Health Manag       Date:  2019-06       Impact factor: 2.459

4.  Improvements in anthropometric measures and gastrointestinal tolerance in patients with cystic fibrosis by using a digestive enzyme cartridge with overnight enteral nutrition.

Authors:  Sara J Hendrix; Patrick A Flume; Eric R First; Albert Archie Stone; Mark Van Buskirk
Journal:  Nutr Clin Pract       Date:  2022-02-24       Impact factor: 3.204

Review 5.  Impact of Liver and Pancreas Diseases on Nutritional Status.

Authors:  Pablo Cañamares-Orbis; Vanesa Bernal-Monterde; Olivia Sierra-Gabarda; Diego Casas-Deza; Guillermo Garcia-Rayado; Luis Cortes; Alberto Lué
Journal:  Nutrients       Date:  2021-05-13       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.